Related Experiment Video
Updated: Aug 10, 2026

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation
Published on: August 11, 2018
Compatibility and stability of fentanyl admixtures in polypropylene syringes
G M Peterson1, K A Miller, J G Galloway
1Tasmanian School of Pharmacy, University of Tasmania, Hobart, Australia.
Objective:
To determine the physicochemical stability of fentanyl in combination with midazolam and either hyoscine butylbromide or metoclopramide, and stored in 30 ml polypropylene syringes.
Methods:
Solutions containing approximately 40 microg/ ml of fentanyl in combination with midazolam (approximately 600 microg/ml) and either metoclopramide (approximately 700 microg/l) or hyoscine (approximately 850 microg/ml) were prepared from commercial ampoules of the drugs. The solutions were stored, in triplicate, in the dark at 32 degrees C (to simulate usage conditions) for 10 days, and the concentration of each constituent drug was periodically determined using a stability-indicating high-performance liquid chromatography assay.
Results:
The combinations were relatively stable, with all drugs maintaining over 90% of their initial chemical potency for at least 1 week. There were no evident changes in either the physical appearance or pH values of the solutions over the course of the study.
Conclusions:
On the basis of physicochemical stability, polypropylene syringes containing fentanyl with midazolam and either hyoscine butylbromide or metoclopramide can be safely prepared and stored at or below 32 degrees C for periods of up to 1 week prior to use by palliative care patients receiving the drugs via a portable subcutaneous infusion device.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Site-Targeted Drug Delivery Systems: Polymeric Carriers

